Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks
Abstract
:1. Introduction
2. Materials and Methods
2.1. Boolean Implication Networks
2.2. NSCLC Patient Cohorts
2.2.1. NSCLC Patient Cohort GSE31800
2.2.2. NSCLC Patient Cohort GSE28582
2.2.3. Xu’s Lung Adenocarcinoma (LUAD) Patient Cohort
2.2.4. TCGA
2.3. Graph Theory Centrality Metrics
2.3.1. Degree Centrality
2.3.2. Eigenvector Centrality
2.3.3. Betweenness Centrality
2.3.4. Closeness Centrality
2.3.5. VoteRank Centrality
2.4. CRISPR-Cas9 Knockout Assays
2.5. RNAi Knockdown Assays
2.6. Statistical Methods
3. Results
3.1. Multi-Omics Networks of NSCLC Patient Cohorts
3.2. Association of Centrality Metrics with Tumorigenesis, Proliferation, and Patient Survival
3.3. Distributions of Multi-Omics Network Centrality Metrics of Therapeutic Targets
3.4. Clinical Relevance of Multi-Omics Network Centrality
3.5. Important Hub Genes in NSCLC
4. Discussion
5. Conclusions
6. Patents
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lung Cancer—Non-Small Cell: Statistics. Available online: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics (accessed on 23 May 2022).
- Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Watkins, T.B.K.; Veeriah, S.; Shafi, S.; Johnson, D.H.; Mitter, R.; Rosenthal, R.; et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 376, 2109–2121. [Google Scholar] [CrossRef] [Green Version]
- Wood, S.L.; Pernemalm, M.; Crosbie, P.A.; Whetton, A.D. Molecular histology of lung cancer: From targets to treatments. Cancer Treat. Rev. 2015, 41, 361–375. [Google Scholar] [CrossRef] [PubMed]
- Forde, P.M.; Chaft, J.E.; Smith, K.N.; Anagnostou, V.; Cottrell, T.R.; Hellmann, M.D.; Zahurak, M.; Yang, S.C.; Jones, D.R.; Broderick, S.; et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N. Engl. J. Med. 2018, 378, 1976–1986. [Google Scholar] [CrossRef] [PubMed]
- Hellmann, M.D.; Rizvi, N.A.; Goldman, J.W.; Gettinger, S.N.; Borghaei, H.; Brahmer, J.R.; Ready, N.E.; Gerber, D.E.; Chow, L.Q.; Juergens, R.A.; et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017, 18, 31–41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019, 37, 537–546. [Google Scholar] [CrossRef]
- Mok, T.S.K.; Wu, Y.L.; Kudaba, I.; Kowalski, D.M.; Cho, B.C.; Turna, H.Z.; Castro, G., Jr.; Srimuninnimit, V.; Laktionov, K.K.; Bondarenko, I.; et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 2019, 393, 1819–1830. [Google Scholar] [CrossRef]
- FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer (accessed on 18 October 2021).
- Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.R.; Bharat, A.; Bruno, D.S.; Chang, J.Y.; Chirieac, L.R.; D’Amico, T.A.; et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J. Natl. Compr. Cancer Netw. JNCCN 2021, 19, 254–266. [Google Scholar] [CrossRef]
- NCCN Guidelines, Version: 3.2022. Available online: https://www.nccn.org/guidelines/category_1 (accessed on 28 June 2022).
- Kuenzi, B.M.; Ideker, T. A census of pathway maps in cancer systems biology. Nat. Rev. Cancer 2020, 20, 233–246. [Google Scholar] [CrossRef]
- Wan, Y.W.; Beer, D.G.; Guo, N.L. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma. Lung Cancer 2012, 76, 98–105. [Google Scholar] [CrossRef]
- Guo, N.L.; Dowlati, A.; Raese, R.A.; Dong, C.; Chen, G.; Beer, D.G.; Shaffer, J.; Singh, S.; Bokhary, U.; Liu, L.; et al. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine 2018, 32, 102–110. [Google Scholar] [CrossRef]
- Starzer, A.M.; Berghoff, A.S. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open 2020, 4, e000629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buchan, S.L.; Rogel, A.; Al-Shamkhani, A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 2017, 131, 39–48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burris, H.A.; Infante, J.R.; Ansell, S.M.; Nemunaitis, J.J.; Weiss, G.R.; Villalobos, V.M.; Sikic, B.I.; Taylor, M.H.; Northfelt, D.W.; Carson, W.E., 3rd; et al. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 2028–2036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bullock, T.N. Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr. Opin. Immunol. 2017, 45, 82–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahrends, T.; Bąbała, N.; Xiao, Y.; Yagita, H.; van Eenennaam, H.; Borst, J. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016, 76, 2921–2931. [Google Scholar] [CrossRef] [Green Version]
- Borst, J.; Hendriks, J.; Xiao, Y. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 2005, 17, 275–281. [Google Scholar] [CrossRef]
- Buchan, S.L.; Fallatah, M.; Thirdborough, S.M.; Taraban, V.Y.; Rogel, A.; Thomas, L.J.; Penfold, C.A.; He, L.Z.; Curran, M.A.; Keler, T.; et al. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8(+) T-Cell-Driven Antitumor Immunity. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2018, 24, 2383–2394. [Google Scholar] [CrossRef] [Green Version]
- Lutfi, F.; Wu, L.; Sunshine, S.; Cao, X. Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation. Front. Immunol. 2021, 12, 715909. [Google Scholar] [CrossRef]
- Deng, Y.; Chatterjee, B.; Zens, K.; Zdimerova, H.; Müller, A.; Schuhmachers, P.; Ligeon, L.A.; Bongiovanni, A.; Capaul, R.; Zbinden, A.; et al. CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion. Blood 2021, 137, 3225–3236. [Google Scholar] [CrossRef]
- Grant, E.J.; Nüssing, S.; Sant, S.; Clemens, E.B.; Kedzierska, K. The role of CD27 in anti-viral T-cell immunity. Curr. Opin. Virol. 2017, 22, 77–88. [Google Scholar] [CrossRef] [PubMed]
- Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat. Rev. Immunol. 2020, 20, 651–668. [Google Scholar] [CrossRef] [PubMed]
- Marin-Acevedo, J.A.; Dholaria, B.; Soyano, A.E.; Knutson, K.L.; Chumsri, S.; Lou, Y. Next generation of immune checkpoint therapy in cancer: New developments and challenges. J. Hematol. Oncol. 2018, 11, 39. [Google Scholar] [CrossRef]
- Ye, Q.; Falatovich, B.; Singh, S.; Ivanov, A.V.; Eubank, T.D.; Guo, N.L. A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2021, 23, 219. [Google Scholar] [CrossRef]
- Ye, Q.; Singh, S.; Qian, P.R.; Guo, N.L. Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer. Cancers 2021, 13, 4296. [Google Scholar] [CrossRef]
- Wang, Z.; Wei, Y.; Zhang, R.; Su, L.; Gogarten, S.M.; Liu, G.; Brennan, P.; Field, J.K.; McKay, J.D.; Lissowska, J.; et al. Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 2018, 32, 93–101. [Google Scholar] [CrossRef] [Green Version]
- Fan, Y.; Kao, C.; Yang, F.; Wang, F.; Yin, G.; Wang, Y.; He, Y.; Ji, J.; Liu, L. Integrated Multi-Omics Analysis Model to Identify Biomarkers Associated With Prognosis of Breast Cancer. Front. Oncol. 2022, 12, 899900. [Google Scholar] [CrossRef] [PubMed]
- Guo, N.L.; Wan, Y.W.; Bose, S.; Denvir, J.; Kashon, M.L.; Andrew, M.E. A novel network model identified a 13-gene lung cancer prognostic signature. Int. J. Comput. Biol. Drug Des. 2011, 4, 19–39. [Google Scholar] [CrossRef]
- Guo, N.L.; Wan, Y.W. Pathway-based identification of a smoking associated 6-gene signature predictive of lung cancer risk and survival. Artif. Intell. Med. 2012, 55, 97–105. [Google Scholar] [CrossRef] [Green Version]
- Starczynowski, D.T.; Lockwood, W.W.; Delehouzee, S.; Chari, R.; Wegrzyn, J.; Fuller, M.; Tsao, M.S.; Lam, S.; Gazdar, A.F.; Lam, W.L.; et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J. Clin. Investig. 2011, 121, 4095–4105. [Google Scholar] [CrossRef]
- Vosse, S. CGHbase: Base Functions and Classes for arrayCGH Data Analysis; R Package Version 1.46.0; The R Foundation: Vienna, Austria, 2021. [Google Scholar]
- Van De Wiel, M.A.; Kim, K.I.; Vosse, S.J.; Van Wieringen, W.N.; Wilting, S.M.; Ylstra, B. CGHcall: Calling Aberrations for Array CGH Tumor Profiles; R Package Version 2.48.0; The R Foundation: Vienna, Austria, 2021. [Google Scholar]
- Micke, P.; Edlund, K.; Holmberg, L.; Kultima, H.G.; Mansouri, L.; Ekman, S.; Bergqvist, M.; Scheibenflug, L.; Lamberg, K.; Myrdal, G.; et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2011, 6, 1833–1840. [Google Scholar] [CrossRef] [Green Version]
- Jabs, V.; Edlund, K.; Konig, H.; Grinberg, M.; Madjar, K.; Rahnenfuhrer, J.; Ekman, S.; Bergkvist, M.; Holmberg, L.; Ickstadt, K.; et al. Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS ONE 2017, 12, e0187246. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.; Li, M.; Hadley, D.; Liu, R.; Glessner, J.; Grant, S.F.; Hakonarson, H.; Bucan, M. PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007, 17, 1665–1674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, J.Y.; Zhang, C.; Wang, X.; Zhai, L.; Ma, Y.; Mao, Y.; Qian, K.; Sun, C.; Liu, Z.; Jiang, S.; et al. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell 2020, 182, 245–261.e217. [Google Scholar] [CrossRef]
- Walter, R.F.; Werner, R.; Vollbrecht, C.; Hager, T.; Flom, E.; Christoph, D.C.; Schmeller, J.; Schmid, K.W.; Wohlschlaeger, J.; Mairinger, F.D. ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology. PLoS ONE 2016, 11, e0165181. [Google Scholar] [CrossRef] [Green Version]
- Saviozzi, S.; Cordero, F.; Lo Iacono, M.; Novello, S.; Scagliotti, G.V.; Calogero, R.A. Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer 2006, 6, 200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, Y.C.; Ding, Y.; Dong, L.; Zhu, L.J.; Jensen, R.V.; Hsiao, L.L. Differential expression patterns of housekeeping genes increase diagnostic and prognostic value in lung cancer. PeerJ 2018, 6, e4719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vasaikar, S.V.; Straub, P.; Wang, J.; Zhang, B. LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018, 46, D956–D963. [Google Scholar] [CrossRef] [Green Version]
- Hagberg, A.; Swart, P.; Chult, D.S. Exploring Network Structure, Dynamics, and Function Using NetworkX; Los Alamos National Lab. (LANL): Los Alamos, NM, USA, 2008. [Google Scholar]
- Krackhardt, D. Assessing the Political Landscape: Structure, Cognition, and Power in Organizations. Adm. Sci. Q. 1990, 35, 342. [Google Scholar] [CrossRef] [Green Version]
- Bonacich, P.; Lloyd, P. Eigenvector centrality and structural zeroes and ones: When is a neighbor not a neighbor? Soc. Netw. 2015, 43, 86–90. [Google Scholar] [CrossRef]
- Aguirre, J.; Papo, D.; Buldú, J.M. Successful strategies for competing networks. Nat. Phys. 2013, 9, 230–234. [Google Scholar] [CrossRef] [Green Version]
- Bonacich, P.; Lloyd, P. Eigenvector-like measures of centrality for asymmetric relations. Soc. Netw. 2001, 23, 191–201. [Google Scholar] [CrossRef]
- Freeman, L.C. Centrality in social networks conceptual clarification. Soc. Netw. 1978, 1, 215–239. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.-X.; Chen, D.-B.; Dong, Q.; Zhao, Z.-D. Identifying a set of influential spreaders in complex networks. Sci. Rep. 2016, 6, 27823. [Google Scholar] [CrossRef] [PubMed]
- Meyers, R.M.; Bryan, J.G.; McFarland, J.M.; Weir, B.A.; Sizemore, A.E.; Xu, H.; Dharia, N.V.; Montgomery, P.G.; Cowley, G.S.; Pantel, S.; et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 2017, 49, 1779–1784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dempster, J.M.; Rossen, J.; Kazachkova, M.; Pan, J.; Kugener, G.; Root, D.E.; Tsherniak, A. Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines. bioRxiv 2019. [Google Scholar] [CrossRef]
- Ye, Q.; Guo, N.L. Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. Cancers 2022, 14, 3123. [Google Scholar] [CrossRef]
- Chen, J.; Bardes, E.E.; Aronow, B.J.; Jegga, A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009, 37, W305–W311. [Google Scholar] [CrossRef] [Green Version]
- Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature 2018, 553, 446–454. [Google Scholar] [CrossRef]
- Emens, L.A. Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. J. Natl. Cancer Inst. 2021, 113, 1601–1603. [Google Scholar] [CrossRef]
- Clote, P. Are RNA networks scale-free? J. Math. Biol. 2020, 80, 1291–1321. [Google Scholar] [CrossRef] [Green Version]
- Sachs, K.; Perez, O.; Pe’er, D.; Lauffenburger, D.A.; Nolan, G.P. Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005, 308, 523–529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Altenbuchinger, M.; Weihs, A.; Quackenbush, J.; Grabe, H.J.; Zacharias, H.U. Gaussian and Mixed Graphical Models as (multi-)omics data analysis tools. Biochim. Biophys. Acta. Gene Regul. Mech. 2020, 1863, 194418. [Google Scholar] [CrossRef] [PubMed]
- Chickering, D.M.; Meek, C.; Heckerman, D. Large-sample learning of bayesian networks is np-hard. J. Mach. Learn. Res. 2004, 5, 1287–1330. [Google Scholar]
- Sahoo, D.; Seita, J.; Bhattacharya, D.; Inlay, M.A.; Weissman, I.L.; Plevritis, S.K.; Dill, D.L. MiDReG: A method of mining developmentally regulated genes using Boolean implications. Proc. Natl. Acad. Sci. USA 2010, 107, 5732–5737. [Google Scholar] [CrossRef] [Green Version]
- Kwon, M.J.; Seo, J.; Kim, Y.J.; Kwon, M.J.; Choi, J.Y.; Kim, T.E.; Lee, D.H.; Park, S.; Shin, Y.K.; Han, J.; et al. Prognostic significance of CD151 overexpression in non-small cell lung cancer. Lung Cancer 2013, 81, 109–116. [Google Scholar] [CrossRef]
- Sandfeld-Paulsen, B.; Jakobsen, K.R.; Bæk, R.; Folkersen, B.H.; Rasmussen, T.R.; Meldgaard, P.; Varming, K.; Jørgensen, M.M.; Sorensen, B.S. Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2016, 11, 1701–1710. [Google Scholar] [CrossRef] [Green Version]
- Zhu, J.; Cai, T.; Zhou, J.; Du, W.; Zeng, Y.; Liu, T.; Fu, Y.; Li, Y.; Qian, Q.; Yang, X.H.; et al. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer. J. Exp. Clin. Cancer Res. CR 2021, 40, 192. [Google Scholar] [CrossRef]
- Peng, D.; Li, P.C.; Liu, T.; Zeng, H.S.; Fei, Y.J.; Liu, Z.X.; Zuo, H.J. Key Role of CD151-integrin Complex in Lung Cancer Metastasis and Mechanisms Involved. Curr. Med. Sci. 2020, 40, 1148–1155. [Google Scholar] [CrossRef]
- Lin, W.H.; Chang, Y.W.; Hong, M.X.; Hsu, T.C.; Lee, K.C.; Lin, C.; Lee, J.L. STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis. Oncogene 2021, 40, 791–805. [Google Scholar] [CrossRef]
- Silva, P.M.A.; Bousbaa, H. BUB3, beyond the Simple Role of Partner. Pharmaceutics 2022, 14, 1084. [Google Scholar] [CrossRef]
- Kraus, F.; Roy, K.; Pucadyil, T.J.; Ryan, M.T. Function and regulation of the divisome for mitochondrial fission. Nature 2021, 590, 57–66. [Google Scholar] [CrossRef]
- Hu, M.; Zhao, Y.; Cao, Y.; Tang, Q.; Feng, Z.; Ni, J.; Zhou, X. DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells. Cancer Sci. 2020, 111, 3588–3599. [Google Scholar] [CrossRef]
- Romani, P.; Nirchio, N.; Arboit, M.; Barbieri, V.; Tosi, A.; Michielin, F.; Shibuya, S.; Benoist, T.; Wu, D.; Hindmarch, C.C.T.; et al. Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance. Nat. Cell Biol. 2022, 24, 168–180. [Google Scholar] [CrossRef]
- Li, Y.; Shen, Y.; Xie, M.; Wang, B.; Wang, T.; Zeng, J.; Hua, H.; Yu, J.; Yang, M. LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and EIF2S1. Signal Transduct. Target. Ther. 2022, 7, 30. [Google Scholar] [CrossRef] [PubMed]
- Du, W.; Zhu, J.; Zeng, Y.; Liu, T.; Zhang, Y.; Cai, T.; Fu, Y.; Zhang, W.; Zhang, R.; Liu, Z.; et al. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. Cell Death Differ. 2021, 28, 1284–1300. [Google Scholar] [CrossRef]
- Sekimoto, N.; Suzuki, Y.; Sugano, S. Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma. J. Cancer 2017, 8, 4125–4140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zou, W.; Zhang, X.; Wang, Y.; Yan, L.; Wu, X.; Yang, R.; Li, Y.; Zhang, J.; Chen, J. NMT1 Enhances the Stemness of NSCLC Cells by Activating the PI3K/AKT Pathway. Pharmacology 2022, 107, 486–494. [Google Scholar] [CrossRef]
- Halder, S.K.; Anumanthan, G.; Maddula, R.; Mann, J.; Chytil, A.; Gonzalez, A.L.; Washington, M.K.; Moses, H.L.; Beauchamp, R.D.; Datta, P.K. Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Cancer Res. 2006, 66, 6156–6166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jin, L.; Datta, P.K. Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21(Cip1) by modulating the transcription factor Sp1. Cell Cycle 2014, 13, 3909–3920. [Google Scholar] [CrossRef] [Green Version]
- Hu, Q.; Tian, T.; Leng, Y.; Tang, Y.; Chen, S.; Lv, Y.; Liang, J.; Liu, Y.; Liu, T.; Shen, L.; et al. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer. Cell. Mol. Biol. Lett. 2022, 27, 71. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Mei, Q.; Ai, Y.Q.; Li, R.Q.; Chang, L.; Li, Y.F.; Xia, Y.X.; Li, W.H.; Chen, Y. Identification of lung cancer oncogenes based on the mRNA expression and single nucleotide polymorphism profile data. Neoplasma 2015, 62, 966–973. [Google Scholar] [CrossRef] [PubMed]
- Gao, P.; Zou, K.; Xiao, L.; Zhou, H.; Xu, X.; Zeng, Z.; Zhang, W. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Int. Immunopharmacol. 2022, 110, 108954. [Google Scholar] [CrossRef] [PubMed]
- Badr, H.; Blutrich, R.; Chan, K.; Tong, J.; Taylor, P.; Zhang, W.; Kafri, R.; Röst, H.L.; Tsao, M.S.; Moran, M.F. Proteomic Characterization of a Candidate Polygenic Driver of Metabolism in Non-small Cell Lung Cancer. J. Mol. Biol. 2022, 434, 167636. [Google Scholar] [CrossRef]
- Jankova, L.; Dent, O.F.; Molloy, M.P.; Chan, C.; Chapuis, P.H.; Howell, V.M.; Clarke, S.J. Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. Proteom. Clin. Appl. 2015, 9, 1078–1086. [Google Scholar] [CrossRef] [PubMed]
- McShane, L.M.; Altman, D.G.; Sauerbrei, W.; Taube, S.E.; Gion, M.; Clark, G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 2005, 97, 1180–1184. [Google Scholar] [CrossRef]
Patient Cohort | Network (Number of Patient Samples) | Number of Network Nodes | Number of Network Edges |
---|---|---|---|
GSE28582 [37,38] | CNV–CNV (n = 100) | 11,533 | 3,228,054 |
CNV-mediated GE (n = 100) | 20,836 | 3,102,789 | |
mRNA co-expression (n = 100) | 15,297 | 48,373,448 | |
GSE31800 [34] | CNV–CNV (n = 271) | 19,344 | 20,950,447 |
CNV-mediated GE (n = 49) | 17,442 | 2,421,110 | |
mRNA co-expression (n = 49) | 15,180 | 4,541,858 | |
Xu’s LUAD [40] | NATs: mRNA co-expression (n = 49) | 12,408 | 20,419,308 |
NATs: mRNA-mediated protein expression (n = 49) | 13,254 | 436,488 | |
NATs: Protein co-expression (n = 103) | 2206 | 785,204 | |
Tumors: mRNA co-expression (n = 51) | 11,938 | 16,101,406 | |
Tumors: mRNA-mediated protein expression (n = 51) | 13,047 | 1,501,406 | |
Tumors: Protein co-expression (n = 103) | 3072 | 2,273,792 |
Tumorigenesis—Differential mRNA Expression in Tumors vs. NATs (n = 51) | Degree Centrality | In-Degree Centrality | Out-Degree Centrality | Eigenvector Centrality | Betweenness Centrality | Closeness Centrality | VoteRank Centrality | |
---|---|---|---|---|---|---|---|---|
CNV–CNV networks | CNV–CNV network (GSE28582, n = 100) | neg | neg | neg | - | neg | - | pos |
CNV–CNV network (GSE31800, n = 271) | - | - | - | - | - | - | - | |
CNV-mediated GE networks | CNV-mediated GE network (GSE28582, n = 100) | - | pos | neg | pos | - | pos | pos |
CNV-mediated GE network (GSE31800, n = 49) | pos | pos | pos | pos | pos | - | neg | |
mRNA co-expression networks | mRNA co-expression network (GSE28582, n = 100) | pos | pos | pos | pos | pos | pos | - |
mRNA co-expression network (GSE31800, n = 49) | - | - | - | pos | - | pos | - | |
mRNA co-expression networks in Xu’s LUAD tumors and NATs | mRNA co-expression network in LUAD tumors (n=51) | pos | pos | pos | pos | - | pos | - |
mRNA co-expression network in LUAD NATs (n=49) | pos | pos | pos | pos | pos | pos | neg | |
mRNA-mediated protein expression networks in Xu’s LUAD tumors and NATs | mRNA-mediated protein expression network in LUAD tumors (n=51) | pos | pos | - | pos | pos | pos | pos |
mRNA-mediated protein expression network in LUAD NATs (n = 49) | pos | pos | - | - | - | pos | - | |
Protein co-expression networks in Xu’s LUAD tumors and NATs | Protein co-expression network in LUAD tumors (n = 103) | pos | pos | pos | pos | pos | pos | - |
Protein co-expression network in LUAD NATs (n = 103) | pos | pos | pos | pos | - | pos | - |
Tumorigenesis—Differential Protein Expression in Tumors vs. NATs (n = 103) | Degree Centrality | In-Degree Centrality | Out-Degree Centrality | Eigenvector Centrality | Betweenness Centrality | Closeness Centrality | VoteRank Centrality | |
---|---|---|---|---|---|---|---|---|
CNV–CNV networks | CNV–CNV network (GSE28582, n = 100) | neg | neg | neg | - | neg | neg | pos |
CNV–CNV network (GSE31800, n = 271) | neg | neg | neg | neg | neg | - | - | |
CNV-mediated GE networks | CNV-mediated GE network (GSE28582, n = 100) | - | pos | neg | pos | - | pos | pos |
CNV-mediated GE network (GSE31800, n = 49) | - | - | - | - | - | - | - | |
mRNA co-expression networks | mRNA co-expression network (GSE28582, n = 100) | pos | pos | pos | pos | - | pos | - |
mRNA co-expression network (GSE31800, n = 49) | neg | neg | neg | neg | neg | - | pos | |
mRNA co-expression networks in Xu’s LUAD tumors and NATs | mRNA co-expression network in LUAD tumors (n = 51) | - | - | - | - | neg | - | pos |
mRNA co-expression network in LUAD NATs (n = 49) | pos | pos | pos | pos | pos | pos | neg | |
mRNA-mediated protein expression networks in Xu’s LUAD tumors and NATs | mRNA-mediated protein expression network in LUAD tumors (n = 51) | pos | pos | neg | pos | pos | pos | pos |
mRNA-mediated protein expression network in LUAD NATs (n = 49) | - | - | - | - | - | - | - | |
Protein co-expression networks in Xu’s LUAD tumors and NATs | Protein co-expression network in LUAD tumors (n = 103) | pos | pos | pos | pos | - | pos | - |
Protein co-expression network in LUAD NATs (n = 103) | pos | pos | pos | pos | - | pos | - |
Proliferation-CRISPR-Cas9 (n = 94) | Degree Centrality | In-Degree Centrality | Out-Degree Centrality | Eigenvector Centrality | Betweenness Centrality | Closeness Centrality | VoteRank Centrality | |
---|---|---|---|---|---|---|---|---|
CNV–CNV networks | CNV–CNV network (GSE28582, n = 100) | pos (61/94) | pos (61/94) | pos (61/94) | pos (9/94) | pos (94/94) | pos (39/94) | neg (93/94) |
CNV–CNV network (GSE31800, n = 271) | pos (94/94) | pos (94/94) | pos (94/94) | pos (94/94) | pos (94/94) | pos (94/94) | neg (94/94) | |
CNV-mediated GE networks | CNV-mediated GE network (GSE28582, n = 100) | neg (40/94) | neg (94/94) | pos (72/94) | neg (94/94) | - | neg (91/94) | neg (43/94) |
CNV-mediated GE network (GSE31800, n = 49) | pos (90/94) | neg (72/94) | pos (94/94) | neg (76/94) | pos (15/94) | neg (92/94) | neg (21/94) | |
mRNA co-expression networks | mRNA co-expression network (GSE28582, n = 100) | neg (94/94) | neg (94/94) | neg (94/94) | neg (94/94) | neg (12/94) | neg (94/94) | pos (94/94) |
mRNA co-expression network (GSE31800, n = 49) | - | - | - | neg (94/94) | pos (81/94) | neg (94/94) | pos (4/94) | |
mRNA co-expression networks in Xu’s LUAD tumors and NATs | mRNA co-expression network in LUAD tumors (n = 51) | neg (64/94) | neg (64/94) | neg (64/94) | neg (91/94) | pos (6/94) | neg (76/94) | - |
mRNA co-expression network in LUAD NATs (n = 49) | neg (94/94) | neg (94/94) | neg (94/94) | neg (94/94) | neg (38/94) | neg (94/94) | pos (92/94) | |
mRNA-mediated protein expression networks in Xu’s LUAD tumors and NATs | mRNA-mediated protein expression network in LUAD tumors (n = 51) | neg (94/94) | neg (94/94) | pos (94/94) | neg (94/94) | neg (94/94) | neg (94/94) | neg (94/94) |
mRNA-mediated protein expression network in LUAD NATs (n = 49) | neg (94/94) | neg (94/94) | pos (94/94) | neg (94/94) | neg (94/94) | neg (94/94) | neg (30/94) | |
Protein co-expression networks in Xu’s LUAD tumors and NATs | Protein co-expression network in LUAD tumors (n = 103) | - | - | - | - | - | - | neg (21/94) |
Protein co-expression network in LUAD NATs (n = 103) | neg (93/94) | neg (93/94) | neg (93/94) | neg (94/94) | - | neg (75/94) | - |
Proliferation—RNAi (n = 92) | Degree Centrality | In-Degree Centrality | Out-Degree Centrality | Eigenvector Centrality | Betweenness Centrality | Closeness Centrality | VoteRank Centrality | |
---|---|---|---|---|---|---|---|---|
CNV–CNV networks | CNV–CNV network (GSE28582, n = 100) | pos (17/92) | pos (17/92) | pos (17/92) | - | pos (88/92) | pos (8/92) | neg (91/92) |
CNV–CNV network (GSE31800, n = 271) | pos (66/92) | pos (66/92) | pos (66/92) | pos (70/92) | pos (82/92) | pos (67/92) | neg (5/92) | |
CNV-mediated GE networks | CNV-mediated GE network (GSE28582, n = 100) | neg (27/92) | neg (92/92) | pos (11/92) | neg (92/92) | - | neg (91/92) | - |
CNV-mediated GE network (GSE31800, n = 49) | pos (1/92) | neg (12/92) | pos (9/92) | neg (9/92) | pos (1/92) | neg (65/92) | pos (1/92) | |
mRNA co-expression networks | mRNA co-expression network (GSE28582, n = 100) | neg (92/92) | neg (92/92) | neg (92/92) | neg (92/92) | neg (80/92) | neg (92/92) | pos (92/92) |
mRNA co-expression network (GSE31800, n = 49) | neg (24/92) | neg (24/92) | neg (24/92) | neg (74/92) | pos (2/92) | neg (92/92) | pos (6/92) | |
mRNA co-expression networks in Xu’s LUAD tumors and NATs | mRNA co-expression network in LUAD tumors (n = 51) | - | - | - | neg (1/92) | pos (33/92) | - | neg (27/92) |
mRNA co-expression network in LUAD NATs (n = 49) | neg (92/92) | neg (92/92) | neg (92/92) | neg (92/92) | neg (82/92) | neg (92/92) | pos (78/92) | |
mRNA-mediated protein expression networks in Xu’s LUAD tumors and NATs | mRNA-mediated protein expression network in LUAD tumors (n = 51) | neg (92/92) | neg (92/92) | pos (92/92) | neg (92/92) | neg (92/92) | neg (92/92) | neg (89/92) |
mRNA-mediated protein expression network in LUAD NATs (n = 49) | neg (92/92) | neg (92/92) | pos (92/92) | neg (92/92) | neg (88/92) | neg (92/92) | neg (1/92) | |
Protein co-expression networks in Xu’s LUAD tumors and NATs | Protein co-expression network in LUAD tumors (n = 103) | - | - | - | neg (1/92) | - | - | neg (10/92) |
Protein co-expression network in LUAD NATs (n = 103) | neg (32/92) | neg (32/92) | neg (32/92) | neg (65/92) | neg (1/92) | neg (14/92) | - |
Patient Survival—Hazard Ratio in Combined TCGA–LUAD (n = 515) and TCGA–LUSC (n = 501) | Degree Centrality | In-degree Centrality | Out-Degree Centrality | Eigenvector Centrality | Betweenness Centrality | Closeness Centrality | VoteRank Centrality | |
---|---|---|---|---|---|---|---|---|
CNV–CNV networks | CNV–CNV network (GSE28582, n = 100) | - | - | - | - | - | - | - |
CNV–CNV network (GSE31800, n = 271) | neg | neg | neg | neg | neg | neg | pos | |
CNV-mediated GE networks | CNV-mediated GE network (GSE28582, n = 100) | - | pos | - | pos | - | - | - |
CNV-mediated GE network (GSE31800, n = 49) | neg | - | neg | - | - | - | - | |
mRNA co-expression networks | mRNA co-expression network (GSE28582, n = 100) | pos | pos | pos | pos | - | pos | neg |
mRNA co-expression network (GSE31800, n = 49) | pos | pos | pos | pos | - | pos | - | |
mRNA co-expression networks in Xu’s LUAD tumors and NATs | mRNA co-expression network in LUAD tumors (n = 51) | neg | neg | neg | neg | neg | neg | pos |
mRNA co-expression network in LUAD NATs (n = 49) | - | - | - | - | - | - | pos | |
mRNA-mediated protein expression networks in Xu’s LUAD tumors and NATs | mRNA-mediated protein expression network in LUAD tumors (n = 51) | pos | pos | neg | pos | pos | pos | - |
mRNA-mediated protein expression network in LUAD NATs (n = 49) | pos | pos | neg | pos | pos | pos | - | |
Protein co-expression networks in Xu’s LUAD tumors and NATs | Protein co-expression network in LUAD tumors (n = 103) | - | - | - | pos | - | - | - |
Protein co-expression network in LUAD NATs (n = 103) | pos | pos | pos | pos | pos | pos | neg |
Gene Name | mRNA DE t Statistics in LUAD | mRNA DE Fold Change in LUAD | Protein DE t Statistics in LUAD | Protein DE Fold Change in LUAD | Proliferation% (CRISPR-Cas9) | Proliferation% (RNAi) | Survival Hazard Ratio in TCGA | 95% CI of Survival Hazard Ratio in TCGA |
---|---|---|---|---|---|---|---|---|
BUB3 | 10.45 | 1.78 | 12.50 | 1.05 | 94/94 | 2/92 | 1.26 | [1.02, 1.55] |
DNM1L | 3.10 | 1.29 | 14.21 | 1.08 | 50/94 | 41/92 | 1.17 | [1.01, 1.37] |
EIF2S1 | 5.84 | 1.60 | 15.79 | 1.04 | 94/94 | 70/92 | 1.24 | [1.03, 1.5] |
GALNT2 | 6.50 | 1.92 | 15.87 | 1.10 | 0/94 | 0/92 | 1.28 | [1.12, 1.47] |
KPNB1 | 9.56 | 1.80 | 14.58 | 1.04 | 94/94 | 73/92 | 1.24 | [1.01, 1.52] |
NMT1 | 8.36 | 1.46 | 17.63 | 1.10 | 62/94 | 0/92 | 1.31 | [1, 1.71] |
PFKP | 6.09 | 2.51 | 16.59 | 1.10 | 1/94 | 0/92 | 1.21 | [1.09, 1.34] |
PGAM1 | 3.81 | 1.48 | 20.62 | 1.09 | 94/94 | 1/92 | 1.17 | [1.01, 1.35] |
PTGES3 | 5.79 | 1.49 | 17.46 | 1.10 | 3/94 | 0/92 | 1.24 | [1.03, 1.49] |
STRAP | 5.61 | 1.66 | 18.41 | 1.09 | 84/94 | 8/92 | 1.17 | [1.02, 1.35] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ye, Q.; Guo, N.L. Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks. Biomolecules 2022, 12, 1782. https://doi.org/10.3390/biom12121782
Ye Q, Guo NL. Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks. Biomolecules. 2022; 12(12):1782. https://doi.org/10.3390/biom12121782
Chicago/Turabian StyleYe, Qing, and Nancy Lan Guo. 2022. "Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks" Biomolecules 12, no. 12: 1782. https://doi.org/10.3390/biom12121782